advertisement
Prasanna G 27
Showing records 1 to 25 | Display all abstracts from Prasanna G77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Stacy R; Stacy R
American Journal of Ophthalmology 2018; 192: 113-123
76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Prasanna G
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716
77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Huttner K
American Journal of Ophthalmology 2018; 192: 113-123
76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Ferrara L; Adams C; Adams C
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716
77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Watts J
American Journal of Ophthalmology 2018; 192: 113-123
76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Ehara T
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716
77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Peace J
American Journal of Ophthalmology 2018; 192: 113-123
76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Li B
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716
77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Wirta D; Walters T
American Journal of Ophthalmology 2018; 192: 113-123
76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Yang L; Xiang C
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716
77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Sall K
American Journal of Ophthalmology 2018; 192: 113-123
76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Ng CTH
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716
77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Seaman J; Ni X
American Journal of Ophthalmology 2018; 192: 113-123
76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Kim S
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716
77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Prasanna G
American Journal of Ophthalmology 2018; 192: 113-123
76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Towler C; Topley T
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716
77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Mogi M; Adams C
American Journal of Ophthalmology 2018; 192: 113-123
76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
McAllister C
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716
77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Adams C; Yan JH
American Journal of Ophthalmology 2018; 192: 113-123
76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Ghosh M; Newton R; Newton R
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716
77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Wald M; He Y
American Journal of Ophthalmology 2018; 192: 113-123
76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Stacy R; Stacy R
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716
77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Newton R; Newton R
American Journal of Ophthalmology 2018; 192: 113-123
76843 A Novel Selective Soluble Guanylate Cyclase Activator, MGV354, Lowers Intraocular Pressure in Preclinical Models, Following Topical Ocular Dosing
Rice DS
Investigative Ophthalmology and Visual Science 2018; 59: 1704-1716
77184 A randomized, controlled phase I/II study to evaluate the safety and efficacy of MGV354 for ocular hypertension or glaucoma
Kolega R
American Journal of Ophthalmology 2018; 192: 113-123
